Diabetes consultant group launch empagliflozin audit
Diabetes teams are being invited to take part in a national audit of empagliflozin (Jardiance) launched by the Association of British Clinical Diabetologists (ABCD).
It now means that the organisation is auditing all three from the new class of diabetes drug, SGLT2 inhibitors.
Using modern technologies on the NHS N3 computer network to facilitate easy gathering of anonymised data, ABCD wants to access empagliflozin (Jardiance) in real clinical use in the UK.
The audit aims to find out whether the experience in real clinical use matches the data from phase 3 clinical trials. Clinicians using empagliflozin will be invited to submit the data that they routinely collect as they monitor the progress of their patients, including HbA1c, weight, side effects, to the nationwide audit.
ABCD hopes that the data from the nationwide audit will inform future practice and guidelines.
An IT tool has been developed on the NHS computer network, N3, to make the process user friendly. It will also facilitate easy analysis of locally collected data.
ABCD hopes to gain insight into both the safety and efficacy of empagliflozin.
As with the canagliflozin audit, to improve patient safety, drugmaker Boehringer Ingelheim’s pharmacovigilance team will be alerted automatically of any serious adverse events.
Non-ABCD members are welcome to take part in the audit and will be given access to the on-line audit tool when they register for the audit.
For more information, click here.